Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul 1;26(13):2984-2987.
doi: 10.1016/j.bmcl.2016.05.029. Epub 2016 May 11.

Discovery and characterization of a novel series of N-phenylsulfonyl-1H-pyrrole picolinamides as positive allosteric modulators of the metabotropic glutamate receptor 4 (mGlu4)

Rocco D Gogliotti  1 , Anna L Blobaum  1 , Ryan M Morrison  1 , J Scott Daniels  1 , James M Salovich  1 , Yiu-Yin Cheung  1 , Alice L Rodriguez  1 , Matthew T Loch  1 , P Jeffrey Conn  2 , Craig W Lindsley  3 , Colleen M Niswender  2 , Corey R Hopkins  4
Affiliations

Discovery and characterization of a novel series of N-phenylsulfonyl-1H-pyrrole picolinamides as positive allosteric modulators of the metabotropic glutamate receptor 4 (mGlu4)

Rocco D Gogliotti et al. Bioorg Med Chem Lett. .

Abstract

Herein we report the synthesis and characterization of a novel series of N-phenylsulfonyl-1H-pyrrole picolinamides as novel positive allosteric modulators of mGlu4. We detail our work towards finding phenyl replacements for the core scaffold of previously reported phenyl sulfonamides and phenyl sulfone compounds. Our efforts culminated in the identification of N-(1-((3,4-dimethylphenyl)sulfonyl)-1H-pyrrol-3-yl)picolinamide as a potent PAM of mGlu4.

Keywords: Metabotropic glutamate receptor 4; PK; Phenyl replacement; Positive allosteric modulator (PAM); Pyrrole sulfonamide.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Previously disclosed phenylsulfonamide and phenylsulfone mGlu4 PAMs.
Scheme 1
Scheme 1
Reagents and conditions. (a) Picolinyl chloride·HCl, diisopropylethylamine, CH2Cl2, 24–39%; (b) Pd2(dba)3, XantPhos, HSCH2Ar, diisopropylethylamine, 1,4-dioxane, 100 °C, 51–87%; (c) m-CPBA, CH2Cl2, 38–87%.
Scheme 2
Scheme 2
Reagents and conditions. (a) DBU, ArSO2Cl or BnSO2Cl, CH2Cl2, 50–96%; (b) EtOH, Ra–Ni, 40 psi H2, 2 h; 93–97%; (c) diisopropylethylamine, picolinyl chloride, CH2Cl2, 39–43%.
See this image and copyright information in PMC

References

    1. Niswender CM, Conn PJ. Annu. Rev. Pharmacol. Toxicol. 2010;50:295. - PMC - PubMed
    1. Conn PJ, Lindsley CW, Jones CK. Trends Pharmcol. Sci. 2009;30:25. - PMC - PubMed
    1. Matosin N, Newell KA. Neurosci. Biobehav. Rev. 2013;37:256. - PubMed
    1. Matosin N, Fernandez-Enright F, Frank E, Deng C, Wong J, Huang XF, Newell KA. J. Psychiatry Neurosci. 2014;39:407. - PMC - PubMed
    1. Bear MF, Huber KM, Warren ST. Trends Neurosci. 2004;2004:370. - PubMed

MeSH terms